Reactive oxygen species-regulated glycogen synthase kinase-3β activation contributes to all-trans retinoic acid-induced apoptosis in granulocyte-differentiated HL60 cells

Chi-Yun Wang, Tsan-Tzu Yang, Chia-Ling Chen, Wei-Chieh Lin, Chiou Feng Lin

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

All-trans retionic acid (ATRA) treatment confers disease remission in acute promyelocytic leukemia (APL) patients by inducing granulocytic differentiation, which is followed by cell apoptosis. Although glycogen synthase kinase (GSK)-3β is known to be required for spontaneous cell death in neutrophils, the requirement of GSK-3β activation for the apoptotic effects remains unknown. This question is addressed in the present study using a model of ATRA-induced granulocytic differentiation and apoptosis in APL HL60 cells. ATRA at a therapeutic concentration (1 μM) induced granulocytic differentiation, followed by apoptosis. ATRA treatment caused decreased Mcl-1, caspase-3 activation, and PARP cleavage following the inactivation of phosphatidylinositol 3-kinase/AKT and the activation of GSK-3β. Pharmacologically and genetically inhibiting GSK-3β effectively retarded ATRA-induced Mcl-1 degradation and apoptosis. Additional differentiation inducers, phorbol 12-myristate 13-acetate and dimethyl sulfoxide, also triggered GSK-3β-dependent apoptosis. Mechanistically, ATRA caused the generation of reactive oxygen species (ROS) through increased expression of NADPH oxidase subunits (p47phox and p67phox) to facilitate ATRA-induced GSK-3β activation and cell apoptosis. This study indicates that ROS initiate GSK-3β-dependent apoptosis in granulocyte-differentiated cells after long-term ATRA treatment.

Original languageEnglish
Pages (from-to)86-94
Number of pages9
JournalBiochemical Pharmacology
Volume88
Issue number1
DOIs
Publication statusPublished - Mar 1 2014

Fingerprint

Glycogen Synthase Kinase 3
HL-60 Cells
Tretinoin
Granulocytes
Reactive Oxygen Species
Chemical activation
Apoptosis
Acids
Acute Promyelocytic Leukemia
Phosphatidylinositol 3-Kinase
NADPH Oxidase
Cell death
Therapeutics
Dimethyl Sulfoxide
Caspase 3
Acetates
Neutrophils
Cell Death
Degradation

Keywords

  • Acute promyelocytic leukemia
  • All-trans retionic acid
  • Apoptosis
  • Glycogen synthase kinase-3β
  • NADPH oxidase
  • Reactive oxygen species

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry

Cite this

@article{18f039a5dc254244962fed1ccae17ec0,
title = "Reactive oxygen species-regulated glycogen synthase kinase-3β activation contributes to all-trans retinoic acid-induced apoptosis in granulocyte-differentiated HL60 cells",
abstract = "All-trans retionic acid (ATRA) treatment confers disease remission in acute promyelocytic leukemia (APL) patients by inducing granulocytic differentiation, which is followed by cell apoptosis. Although glycogen synthase kinase (GSK)-3β is known to be required for spontaneous cell death in neutrophils, the requirement of GSK-3β activation for the apoptotic effects remains unknown. This question is addressed in the present study using a model of ATRA-induced granulocytic differentiation and apoptosis in APL HL60 cells. ATRA at a therapeutic concentration (1 μM) induced granulocytic differentiation, followed by apoptosis. ATRA treatment caused decreased Mcl-1, caspase-3 activation, and PARP cleavage following the inactivation of phosphatidylinositol 3-kinase/AKT and the activation of GSK-3β. Pharmacologically and genetically inhibiting GSK-3β effectively retarded ATRA-induced Mcl-1 degradation and apoptosis. Additional differentiation inducers, phorbol 12-myristate 13-acetate and dimethyl sulfoxide, also triggered GSK-3β-dependent apoptosis. Mechanistically, ATRA caused the generation of reactive oxygen species (ROS) through increased expression of NADPH oxidase subunits (p47phox and p67phox) to facilitate ATRA-induced GSK-3β activation and cell apoptosis. This study indicates that ROS initiate GSK-3β-dependent apoptosis in granulocyte-differentiated cells after long-term ATRA treatment.",
keywords = "Acute promyelocytic leukemia, All-trans retionic acid, Apoptosis, Glycogen synthase kinase-3β, NADPH oxidase, Reactive oxygen species",
author = "Chi-Yun Wang and Tsan-Tzu Yang and Chia-Ling Chen and Wei-Chieh Lin and Lin, {Chiou Feng}",
year = "2014",
month = "3",
day = "1",
doi = "10.1016/j.bcp.2013.12.021",
language = "English",
volume = "88",
pages = "86--94",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Reactive oxygen species-regulated glycogen synthase kinase-3β activation contributes to all-trans retinoic acid-induced apoptosis in granulocyte-differentiated HL60 cells

AU - Wang, Chi-Yun

AU - Yang, Tsan-Tzu

AU - Chen, Chia-Ling

AU - Lin, Wei-Chieh

AU - Lin, Chiou Feng

PY - 2014/3/1

Y1 - 2014/3/1

N2 - All-trans retionic acid (ATRA) treatment confers disease remission in acute promyelocytic leukemia (APL) patients by inducing granulocytic differentiation, which is followed by cell apoptosis. Although glycogen synthase kinase (GSK)-3β is known to be required for spontaneous cell death in neutrophils, the requirement of GSK-3β activation for the apoptotic effects remains unknown. This question is addressed in the present study using a model of ATRA-induced granulocytic differentiation and apoptosis in APL HL60 cells. ATRA at a therapeutic concentration (1 μM) induced granulocytic differentiation, followed by apoptosis. ATRA treatment caused decreased Mcl-1, caspase-3 activation, and PARP cleavage following the inactivation of phosphatidylinositol 3-kinase/AKT and the activation of GSK-3β. Pharmacologically and genetically inhibiting GSK-3β effectively retarded ATRA-induced Mcl-1 degradation and apoptosis. Additional differentiation inducers, phorbol 12-myristate 13-acetate and dimethyl sulfoxide, also triggered GSK-3β-dependent apoptosis. Mechanistically, ATRA caused the generation of reactive oxygen species (ROS) through increased expression of NADPH oxidase subunits (p47phox and p67phox) to facilitate ATRA-induced GSK-3β activation and cell apoptosis. This study indicates that ROS initiate GSK-3β-dependent apoptosis in granulocyte-differentiated cells after long-term ATRA treatment.

AB - All-trans retionic acid (ATRA) treatment confers disease remission in acute promyelocytic leukemia (APL) patients by inducing granulocytic differentiation, which is followed by cell apoptosis. Although glycogen synthase kinase (GSK)-3β is known to be required for spontaneous cell death in neutrophils, the requirement of GSK-3β activation for the apoptotic effects remains unknown. This question is addressed in the present study using a model of ATRA-induced granulocytic differentiation and apoptosis in APL HL60 cells. ATRA at a therapeutic concentration (1 μM) induced granulocytic differentiation, followed by apoptosis. ATRA treatment caused decreased Mcl-1, caspase-3 activation, and PARP cleavage following the inactivation of phosphatidylinositol 3-kinase/AKT and the activation of GSK-3β. Pharmacologically and genetically inhibiting GSK-3β effectively retarded ATRA-induced Mcl-1 degradation and apoptosis. Additional differentiation inducers, phorbol 12-myristate 13-acetate and dimethyl sulfoxide, also triggered GSK-3β-dependent apoptosis. Mechanistically, ATRA caused the generation of reactive oxygen species (ROS) through increased expression of NADPH oxidase subunits (p47phox and p67phox) to facilitate ATRA-induced GSK-3β activation and cell apoptosis. This study indicates that ROS initiate GSK-3β-dependent apoptosis in granulocyte-differentiated cells after long-term ATRA treatment.

KW - Acute promyelocytic leukemia

KW - All-trans retionic acid

KW - Apoptosis

KW - Glycogen synthase kinase-3β

KW - NADPH oxidase

KW - Reactive oxygen species

UR - http://www.scopus.com/inward/record.url?scp=84896707473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896707473&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2013.12.021

DO - 10.1016/j.bcp.2013.12.021

M3 - Article

C2 - 24406248

AN - SCOPUS:84896707473

VL - 88

SP - 86

EP - 94

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 1

ER -